142 related articles for article (PubMed ID: 36821759)
1. Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model.
Nadtochiy SM; Stefanos T; Angona RE; Darrow N; Jones CCPK; Feng C; Algahim M; LeMoine D; Westcott R; Anderson B; Swartz MF; Eaton MP
Anesthesiology; 2023 May; 138(5):523-532. PubMed ID: 36821759
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass.
Nadtochiy SM; Stefanos T; Angona RE; Lebedko N; Baldzizhar A; Feng C; Eaton MP
Anesth Analg; 2022 Jul; 135(1):52-59. PubMed ID: 35389372
[TBL] [Abstract][Full Text] [Related]
3. High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood.
Nadtochiy SM; Baldzizhar A; Stefanos T; Feng C; O'Leary KE; Jones-Smith KL; Angona RE; Eaton MP
Anesth Analg; 2021 Feb; 132(2):566-574. PubMed ID: 32833714
[TBL] [Abstract][Full Text] [Related]
4. Delayed concentration effect models for dabigatran anticoagulation.
Eaton MP; Nadtochiy SM; Stefanos T; LeMoine D; Anderson BJ
Paediatr Anaesth; 2022 Oct; 32(10):1113-1120. PubMed ID: 35735989
[TBL] [Abstract][Full Text] [Related]
5. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
[TBL] [Abstract][Full Text] [Related]
6. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
van Wyk V; Neethling WM; Badenhorst PN; Kotzé HF
J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques.
Owings JT; Pollock ME; Gosselin RC; Ireland K; Jahr JS; Larkin EC
Arch Surg; 2000 Sep; 135(9):1042-7. PubMed ID: 10982508
[TBL] [Abstract][Full Text] [Related]
8. Heparinless cardiopulmonary bypass with argatroban in dogs.
Rikitake K; Okazaki Y; Naito K; Ohtsubo S; Natsuaki M; Itoh T
Eur J Cardiothorac Surg; 2004 May; 25(5):819-24. PubMed ID: 15082288
[TBL] [Abstract][Full Text] [Related]
9. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T
Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation management during cross-clamping and bypass.
Lander H; Zammert M; FitzGerald D
Best Pract Res Clin Anaesthesiol; 2016 Sep; 30(3):359-70. PubMed ID: 27650345
[TBL] [Abstract][Full Text] [Related]
11. Rabbit model of cardiopulmonary bypass.
Kim WG; Moon HJ; Won TH; Chee HK
Perfusion; 1999 Mar; 14(2):101-5. PubMed ID: 10338321
[TBL] [Abstract][Full Text] [Related]
12. The effect of ultrafiltration with cardiopulmonary bypass on the removal of dabigatran from the circulation of adult pigs.
DeNino WF; Carter CB; Sievert A; Goss A; Toole JM; Mukherjee R; Uber WE
Perfusion; 2016 Jul; 31(5):424-30. PubMed ID: 26519741
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass.
Pireaux V; Tassignon J; Demoulin S; Derochette S; Borenstein N; Ente A; Fiette L; Douxfils J; Lancellotti P; Guyaux M; Godfroid E
J Am Coll Cardiol; 2019 Oct; 74(17):2178-2189. PubMed ID: 31648711
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
[TBL] [Abstract][Full Text] [Related]
15. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series.
Gernhofer YK; Banks DA; Golts E; Pretorius V
Semin Thorac Cardiovasc Surg; 2020 Winter; 32(4):763-769. PubMed ID: 31610233
[TBL] [Abstract][Full Text] [Related]
16. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
17. The use of bivalirudin for cardiopulmonary bypass anticoagulation in pediatric heparin-induced thrombocytopenia patients.
Gates R; Yost P; Parker B
Artif Organs; 2010 Aug; 34(8):667-9. PubMed ID: 20528853
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
[TBL] [Abstract][Full Text] [Related]
19. [Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Takano H; Miyamoto Y; Kaneko M; Matsuwaka R; Kuratani T; Amemiya A; Nakano S; Matsuda H
Nihon Kyobu Geka Gakkai Zasshi; 1993 Nov; 41(11):2166-73. PubMed ID: 8283086
[TBL] [Abstract][Full Text] [Related]
20. Heparin sensitivity test for patients requiring cardiopulmonary bypass.
DeBois WJ; Liu J; Elmer B; Ebrahimi H; Voevidko L; Lee LY; Krieger KH; Isom WW; Girardi LN
J Extra Corpor Technol; 2006 Dec; 38(4):307-9. PubMed ID: 17312901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
